Poractant alfa

Drug Profile

Poractant alfa

Alternative Names: Curasurf; Curosurf

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiesi; Karolinska Institute
  • Developer Chiesi; Dey Laboratories
  • Class Phospholipids; Pulmonary surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neonatal respiratory distress syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neonatal respiratory distress syndrome

Most Recent Events

  • 16 Mar 2017 Phase-II clinical trials in Neonatal respiratory distress syndrome in Hungary (Inhalation) (EudraCT2016-004547-36)
  • 17 May 2016 Chiesi plans a phase III trial for Neonatal respiratory distress syndrome in Italy (NCT02772081)
  • 25 Feb 2015 Adverse events data from a clinical trial in Neonatal respiratory distress syndrome released by Chiesi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top